BCAX

20.85

2.89% -0.62

Handel nachbörslich: 20.85

Bicara Therapeutics Inc (BCAX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$21.47

Offen:

$21.58

24-Stunden-Volumen:

549.57K

Relative Volume:

1.04

Marktkapitalisierung:

$1.36B

Einnahmen:

Nettoeinkommen (Verlust:

$-137.95M

KGV:

-8.2653

EPS:

-2.5226

Netto-Cashflow:

$-107.11M

1W Leistung:

+9.51%

1M Leistung:

+12.89%

6M Leistung:

+15.64%

1J Leistung:

+97.26%

1-Tages-Spanne:

$20.62

$21.63

1-Wochen-Bereich:

$18.90

$21.63

52-Wochen-Spanne:

$7.80

$21.63

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Firmenname

Bicara Therapeutics Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

617-468-4219

Adresse

116 HUNTINGTON AVENUE SUITE 703, BOSTON

Mitarbeiter

103

Twitter

Nächster Verdiensttermin

2026-03-30

Neueste SEC-Einreichungen

BCAX's Discussions on Twitter

Compare BCAX vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCAX Bicara Therapeutics Inc	20.85	1.41B	0	-137.95M	-107.11M	-2.5226
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-25	Eingeleitet	BofA Securities	Buy
2026-01-29	Eingeleitet	Citizens JMP	Mkt Perform
2026-01-08	Eingeleitet	BTIG Research	Buy
2025-12-18	Eingeleitet	Mizuho	Neutral
2025-08-19	Eingeleitet	Piper Sandler	Overweight
2025-05-23	Hochstufung	Wells Fargo	Underweight → Equal Weight
2025-04-17	Eingeleitet	Wells Fargo	Underweight
2025-02-06	Eingeleitet	Wedbush	Outperform
2024-12-06	Eingeleitet	H.C. Wainwright	Buy
2024-11-05	Eingeleitet	Rodman & Renshaw	Buy
2024-10-08	Eingeleitet	Cantor Fitzgerald	Overweight
2024-10-08	Eingeleitet	Morgan Stanley	Overweight
2024-10-08	Eingeleitet	Stifel	Buy
2024-10-08	Eingeleitet	TD Cowen	Buy

Alle ansehen

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

03:40 AM

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN

03:40 AM

Apr 05, 2026

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com

Apr 05, 2026

Apr 04, 2026

BCAX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st

Apr 03, 2026

Bicara Therapeutics Announces Inducement Grant - National Today

Apr 03, 2026

New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan

Apr 03, 2026

Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN

Apr 03, 2026

Apr 02, 2026

HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - MarketBeat

Apr 02, 2026

Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 01, 2026

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com

Apr 01, 2026

Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget

Apr 01, 2026

Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget

Apr 01, 2026

Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat

Apr 01, 2026

Bicara Therapeutics stock hits 52-week high, reaching $20.42 - investing.com

Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail

Apr 01, 2026

Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN

Apr 01, 2026

Mar 31, 2026

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - Seeking Alpha

Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - MarketBeat

Mar 31, 2026

Wells Fargo Maintains Rating on BCAX, Increases Price Target to - gurufocus.com

Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - MarketBeat

Mar 31, 2026

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - MarketBeat

Mar 31, 2026

Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat

Mar 31, 2026

BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - gurufocus.com

Mar 31, 2026

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 31, 2026

HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - MarketBeat

Mar 31, 2026

Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 31, 2026

H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK

Mar 31, 2026

H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa

Mar 31, 2026

Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Mar 31, 2026

Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK

Mar 31, 2026

Bicara Q4 2025 slides: breakthrough designation, pivotal study data By Investing.com - Investing.com South Africa

Mar 31, 2026

Value Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Key Lessons & Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Bicara Therapeutics (Nasdaq: BCAX) outlines pivotal ficerafusp alfa cancer program - Stock Titan

Mar 30, 2026

Bicara Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat

Mar 30, 2026

Bicara Therapeutics Inc. Files 8-K with SEC Detailing Q4 2025 Financials and Corporate Updates - Minichart

Mar 30, 2026

Bicara Q4 2025 slides: breakthrough designation, pivotal study data - Investing.com

Mar 30, 2026

Bicara Therapeutics Q4 Earnings Call Highlights - MarketBeat

Mar 30, 2026

Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data By Investing.com - Investing.com Australia

Mar 30, 2026

Earnings call transcript: Bicara Therapeutics’ Q4 2025 sees stock surge on promising clinical data - Investing.com Australia

Mar 30, 2026

Bicara Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026

Bicara Therapeutics 2025 Financial Update - AlphaStreet

Mar 30, 2026

Bicara Therapeutics reports fourth quarter and full year 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026

Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results - MarketBeat

Mar 30, 2026

Cash runway to 2029 as Bicara (NASDAQ: BCAX) advances Phase 3 - Stock Titan

Mar 30, 2026

Bicara Therapeutics Inc. initiates Phase 3 trial with 1500 mg QW dose for FORTIFI-HN01 - Traders Union

Mar 30, 2026

Earnings Flash (BCAX) Bicara Therapeutics Posts Q4 Net Loss $0.68 a Share, vs. FactSet Est of $0.67 Loss - marketscreener.com

Mar 30, 2026

Bicara moves head and neck cancer drug into Phase 3 after dose pick - Stock Titan

Mar 30, 2026